Back to results
US 10,519,218 B2Granted
Selective IL-6-trans-signalling inhibitor compositions
AssigneeFerring B.V.
InventorsIan Cottingham, Daniel Plaksin, Jérémy Duboeuf
Life of this patent
Estimating the term…
Abstract
A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
Claims8
A polypeptide dimer comprising two gp130-Fc monomers comprising the amino acid sequence of SEQ ID NO:
- 1, wherein the monomers comprise the gp130 D6 domain corresponding to the amino acids at positions 585-595 of the amino acid sequence of SEQ ID NO:1, an Fc domain hinge region comprising the amino acids at positions 609-612 of the amino acid sequence of SEQ ID NO:1, and the monomers do not comprise a linker between the gp130 D6 domain and the Fc domain hinge region, wherein:
- the polypeptide dimer comprises no greater than 6 mol % of galactose-alpha-1,3-galactose per mole polypeptide.
Dependencies are inferred from the claim text.